{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-040930","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2026-09-01T12:00:25+00:00","discovered_at":"2026-09-01T12:05:02.612529+00:00","generated_at":"2026-09-01T12:05:12.923819+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MIRA Pharmaceuticals reports positive toxicology results for MIRA-55; targets Q1 2027 IND","bullets":["7-day dose-range finding toxicology and toxicokinetic studies of MIRA-55 in rats and dogs completed with positive results.","Rats identified as more sensitive species; dogs showed greater tolerance; systemic exposure confirmed in both.","Results inform dose selection for next phase of IND-enabling program; GLP-compliant studies planned.","Company targets IND submission to FDA for MIRA-55 in Q1 2027, subject to remaining studies.","MIRA-55 is an oral non-opioid candidate for inflammatory pain; DEA has determined it is not a controlled substance."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-040930","json":"https://secwatch.observer/filing/0001493152-26-040930.json","markdown":"https://secwatch.observer/filing/0001493152-26-040930.md","text":"https://secwatch.observer/filing/0001493152-26-040930.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226040930/0001493152-26-040930-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000149315226040930/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-01T12:05:12.923819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}